+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
BALPHARMA

Bal Pharma Share Price

 

 

Bal Pharma live price: ₹83.27. It opened at ₹85 vs previous close ₹84; intraday high/low: ₹85/₹83. The 50 & 200 DMA stand at ₹82.80/₹81.43.

Bal Pharma Performance

  • Today's Low
  • ₹83
  • Today's High
  • ₹85
  • 52 Week Low
  • ₹60
  • 52 Week High
  • ₹105
  • Open Price₹85
  • Previous Close₹84
  • Volume25,136
  • 50 DMA₹82.80
  • 100 DMA₹80.05
  • 200 DMA₹81.43

Bal Pharma Chart

Investment Returns

  • Over 1 Month -9.8%
  • Over 3 Month + 24.49%
  • Over 6 Month + 15.86%
  • Over 1 Year -16.76%

Smart Investing Starts Here Start SIP with Bal Pharma for Steady Growth!

Invest Now

Bal Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 21.1
  • PEG Ratio
  • -1.6
  • Market Cap Cr
  • 133
  • P/B Ratio
  • 1.6
  • Average True Range
  • 4.4
  • EPS
  • 3.95
  • Dividend Yield
  • 1.4
  • MACD Signal
  • 1.46
  • RSI
  • 45.54
  • MFI
  • 36.51

Latest Stock News Updates

Bal Pharma Standalone September 2023 Net Sales at Rs 92.30 crore, up 22.98% Y-o-Y

Bal Pharma Consolidated March 2023 Net Sales at Rs 82.45 crore, up 11.35% Y-o-Y

Bal Pharma Consolidated September 2022 Net Sales at Rs 75.31 crore, up 12.11% Y-o-Y

NULL

Bal Pharma Financials

Bal Pharma Technicals

EMA & SMA

Current Price
₹83.27
-1.21 (-1.43%)
pointer
  • Bearish Moving Average 9
  • Bullish Moving Average 7
  • 20 Day
  • ₹85.80
  • 50 Day
  • ₹82.80
  • 100 Day
  • ₹80.00
  • 200 Day
  • ₹81.40

Resistance and Support

83.77 Pivot Speed
  • R3 87.65
  • R2 86.52
  • R1 84.90
  • S1 82.15
  • S2 81.02
  • S3 79.40

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Bal Pharma has an operating revenue of Rs. 311.66 Cr. on a trailing 12-month basis. An annual revenue growth of 3% is not great, Pre-tax margin of 2% needs improvement, ROE of 7% is fair but needs improvement. The company has a reasonable debt to equity of 39%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 7% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. It has recently broken out of a base in its weekly chart and is trading around 2% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 52 which is a POOR score indicating inconsistency in earnings, a RS Rating of 67 which is FAIR indicating the recent price performance, Buyer Demand at C+ which is evident from recent supply seen, Group Rank of 53 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Bal Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-05-27 Audited Results, Final Dividend & ESOP
2026-02-11 Quarterly Results
2025-11-12 Quarterly Results
2025-08-11 Quarterly Results, ESOP & A.G.M.
2025-05-29 Audited Results & Dividend
Date Purpose Remarks
2025-09-18 FINAL Rs.1.20 per share(12%)Dividend
View Bal Pharma Dividend History Arrow

Bal Pharma Shareholding Pattern

50.86%
0.14%
32.84%
16.16%

Bal Pharma FAQs

Bal Pharma share price is ₹83 As on 28 June, 2026 | 02:27

The Market Cap of Bal Pharma is ₹132.6 Cr As on 28 June, 2026 | 02:27

The P/E ratio of Bal Pharma is 21.1 As on 28 June, 2026 | 02:27

The PB ratio of Bal Pharma is 1.6 As on 28 June, 2026 | 02:27

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23